Aggression and Impulsivity Treatment Guidelines

Evidence-Based Treatment Options

The American Academy of Child and Adolescent Psychiatry recommends risperidone (0.5-3.5 mg/day) for severe aggression in autism spectrum disorder or intellectual disability, with a 69% positive response rate versus 12% on placebo for irritability and aggression 1
Aripiprazole (5-15 mg/day) is FDA-approved for irritability in adolescents aged 13-17 years and children 6-17 with ASD, and shows significant improvement on standardized aggression scales compared to placebo 3
The American Academy of Child and Adolescent Psychiatry suggests divalproex sodium as the preferred adjunctive agent for conduct disorder with aggressive outbursts, with response rates of 53% for mania and mixed episodes 2
Lithium carbonate is an alternative mood stabilizer with FDA approval for adolescents ≥12 years, and can be used for conduct disorder with emotional dysregulation 2

For ADHD with aggression, stimulants are recommended as first-line treatment, as they reduce both ADHD symptoms and antisocial behaviors 2
For autism/intellectual disability with severe aggression, risperidone or aripiprazole are recommended 1, 3
For conduct disorder with emotional dysregulation, divalproex sodium is recommended as adjunctive therapy 2
When using atypical antipsychotics, monitor for metabolic syndrome risk, movement disorders, and prolactin levels 2
When using SSRIs, monitor for behavioral activation/agitation and suicidality, especially in the first months and after dose adjustments 5

Do not prescribe medication for behavioral problems without identifying an underlying psychiatric disorder 4
Do not use quetiapine when evidence-based alternatives exist, as it lacks specific evidence for aggression and impulsivity 2
Do not substitute medication for appropriate behavioral interventions, as combining approaches is moderately more efficacious than medication alone 3